Forty two female patients with strong acne and oiliness were studied all of them were treated with a tablet daily of 2 mg. of cyprosterone Acetate and 0.05 mg of ethinyl oestradiol for 3 weeks and a week without it. We found intolerance to the treatment in 9 out of 42 patients and a high percentage of cure or marked improvement in 96.9% of patients. In conclusion this drug is a good help to the treatment of female acne with seborrheic skin.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tackling antineoplastic drugs' contamination in healthcare settings: New insights on surface cleaning approaches.
J Occup Environ Hyg
January 2025
EPIUnit, Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
Effective decontamination of hospital surfaces is crucial to protect workers from antineoplastic drugs (ADs) since dermal absorption is the main exposure route to these hazardous medicinal products. Sampling after daily cleaning in oncologic settings from a tertiary hospital was initially performed and exhibited low contamination levels; however, cyclophosphamide was still found (up to 957 pg/cm) above the guidance value (100 pg/cm) in four locations, evidencing the need to properly assess and update the cleaning protocols. Then, cleaning efficiencies of six solutions and different protocols were evaluated (including, for the first time, four commercial cleaning solutions/disinfectants not designed specifically for AD removal) after deliberate contamination of three model surfaces with 13 pharmaceuticals: bicalutamide, capecitabine, cyclophosphamide, cyproterone, doxorubicin, etoposide, flutamide, ifosfamide, imatinib, megestrol, mycophenolate mofetil, paclitaxel, and prednisone.
View Article and Find Full Text PDFHigh-Dose Cyproterone Acetate and Intracranial Meningioma: Impact of the Risk Minimisation Measures Implemented in France in 2018-2019.
Pharmacoepidemiol Drug Saf
January 2025
EPI-PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products-ANSM, French National Health Insurance-CNAM), Saint-Denis, France.
Purpose: To measure the impact of national regulatory actions implemented in France in August 2018 and June 2019 to reduce the risk of meningioma associated with the use of cyproterone acetate (CPA).
Methods: Using the French National Healthcare database, we calculated the monthly number of CPA users among cisgender women, men and transgender women in 2010-2021, the monthly proportion of users with cerebral imaging screening, and the annual rate of meningioma surgery associated with CPA use. CPA discontinuations and switches were analysed.
Partial rejuvenation of the spermatogonial stem cell niche after gender-affirming hormone therapy in trans women.
Elife
January 2025
Biology of the Testis (BITE) Laboratory, Genetics, Reproduction and Development (GRAD) Research Group, Vrije Universiteit Brussel, Brussels, Belgium.
Although the impact of gender-affirming hormone therapy (GAHT) on spermatogenesis in trans women has already been studied, data on its precise effects on the testicular environment is poor. Therefore, this study aimed to characterize, through histological and transcriptomic analysis, the spermatogonial stem cell niche of 106 trans women who underwent standardized GAHT, comprising estrogens and cyproterone acetate. A partial dedifferentiation of Sertoli cells was observed, marked by the co-expression of androgen receptor and anti-Müllerian hormone which mirrors the situation in peripubertal boys.
View Article and Find Full Text PDFUPDATE ON MEDICAL TREATMENT OF ENDOMETRIOSIS: NEW DRUGS OR NEW THERAPEUTIC APPROACHES?
Gynecol Obstet Invest
December 2024
Background: No conceptually new drugs for the safe and successful cure of endometriosis are likely to become available soon. Hormonal modulation of ovarian function and suppression of menstruation remain the pillars of disease control. However, existing drugs may be used following novel modalities to limit the consequences of endometriosis progression.
View Article and Find Full Text PDFIs Stopping of Testosterone-Lowering Medication in Men Convicted of Sexual Offenses Associated With an Increase in Recidivism Risk?
Sex Abuse
December 2024
Institute for Sex Research and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
There is some evidence that testosterone-lowering medications (TLM) may be an effective treatment for men convicted of sexual offenses by attenuating paraphilic sexual fantasies and behaviors and reducing the recidivism risk. To date, however, only little is known about the effects of TLM stopping on risk-relevant aspects. Therefore, the current study aimed at examining the recidivism risk as measured by Stable-2007 as well as official records of reoffenses in 29 men having stopped TLM treatment as compared to 37 men with ongoing TLM treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!